sulfadiazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-infectives, sulfonamides | 2500 | 68-35-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.13 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 57 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 684.95 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.29 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.55 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.44 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 7 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 11, 1941 | FDA | LEDERLE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 165.66 | 34.81 | 96 | 1309 | 250914 | 50352805 |
| Lipase increased | 155.67 | 34.81 | 38 | 1367 | 8503 | 50595216 |
| Pancreatitis | 99.02 | 34.81 | 39 | 1366 | 42575 | 50561144 |
| Drug reaction with eosinophilia and systemic symptoms | 95.13 | 34.81 | 34 | 1371 | 28390 | 50575329 |
| Pancytopenia | 44.15 | 34.81 | 28 | 1377 | 84002 | 50519717 |
| Astigmatism | 43.26 | 34.81 | 9 | 1396 | 972 | 50602747 |
| Pneumonia aspiration | 37.69 | 34.81 | 18 | 1387 | 30986 | 50572733 |
| Hepatocellular injury | 37.56 | 34.81 | 17 | 1388 | 25930 | 50577789 |
| Coma | 35.05 | 34.81 | 21 | 1384 | 56858 | 50546861 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 81.03 | 30.52 | 30 | 1223 | 18123 | 29555151 |
| Stevens-Johnson syndrome | 44.58 | 30.52 | 19 | 1234 | 16478 | 29556796 |
| Cerebral toxoplasmosis | 36.19 | 30.52 | 9 | 1244 | 1407 | 29571867 |
| Central pain syndrome | 32.02 | 30.52 | 5 | 1248 | 67 | 29573207 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug reaction with eosinophilia and systemic symptoms | 98.09 | 27.76 | 45 | 2302 | 54172 | 64442213 |
| Toxic epidermal necrolysis | 67.64 | 27.76 | 31 | 2316 | 37135 | 64459250 |
| Pancytopenia | 64.15 | 27.76 | 48 | 2299 | 143261 | 64353124 |
| Cerebral toxoplasmosis | 45.29 | 27.76 | 11 | 2336 | 1815 | 64494570 |
| Drug hypersensitivity | 43.22 | 27.76 | 48 | 2299 | 237767 | 64258618 |
| Astigmatism | 39.81 | 27.76 | 9 | 2338 | 1089 | 64495296 |
| Hepatocellular injury | 31.67 | 27.76 | 20 | 2327 | 45215 | 64451170 |
| Pulmonary venous thrombosis | 30.53 | 27.76 | 5 | 2342 | 108 | 64496277 |
| Infection protozoal | 30.26 | 27.76 | 4 | 2343 | 17 | 64496368 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01EC02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Intermediate-acting sulfonamides |
| ATC | J01EE02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives |
| ATC | J01EE06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives |
| FDA CS | M0020790 | Sulfonamides |
| FDA EPC | N0000175503 | Sulfonamide Antibacterial |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D003049 | Coccidiostats |
| CHEBI has role | CHEBI:33281 | antibiotics |
| CHEBI has role | CHEBI:35441 | antiinfective agents |
| CHEBI has role | CHEBI:35703 | Xenobiotic |
| CHEBI has role | CHEBI:35818 | coccidiostats |
| CHEBI has role | CHEBI:35820 | antiprotozoal drugs |
| CHEBI has role | CHEBI:50502 | dihydropteroate synthase inhibitors |
| CHEBI has role | CHEBI:74234 | sepiapterin reductase inhibitors |
| CHEBI has role | CHEBI:78298 | environmental contaminants |
| CHEBI has role | CHEBI:88188 | allergenic drug |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chorioretinitis | indication | 46627006 | DOID:8886 |
| Skin ulcer | indication | 46742003 | |
| Ulcerative colitis | indication | 64766004 | DOID:8577 |
| Congenital toxoplasmosis | indication | 73893000 | DOID:13336 |
| Toxoplasmosis | indication | 187192000 | DOID:9965 |
| Toxoplasmosis associated with acquired immunodeficiency syndrome | indication | 421666009 | |
| Rheumatic Fever Prevention | indication | ||
| Burn Wound Infections | indication | ||
| Encephalitis due to Toxoplasmosis | indication | ||
| Minor Bacterial Skin Infections | indication | ||
| Collagenous colitis | off-label use | 19311003 | DOID:0060183 |
| Psoriasis with arthropathy | off-label use | 33339001 | |
| Crohn's disease | off-label use | 34000006 | |
| Rheumatoid arthritis | off-label use | 69896004 | DOID:7148 |
| Systemic sclerosis | off-label use | 89155008 | DOID:418 |
| Juvenile rheumatoid arthritis | off-label use | 410795001 | |
| Toxoplasmosis Prevention | off-label use | ||
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Third trimester pregnancy | contraindication | 41587001 | |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Megaloblastic anemia due to folate deficiency | contraindication | 85649008 | DOID:14026 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Superimposed infection | contraindication | 193198003 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Aplastic anemia | contraindication | 306058006 | DOID:12449 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Porphyria | contraindication | 418470004 | |
| Slow acetylator due to N-acetyltransferase enzyme variant | contraindication | 425079005 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Systemic antibacterial action against sensitive organisms to surgery | Indication |
| Dogs | Systemic antibacterial action against sensitive organisms to debridement | Indication |
| Dogs | Control of bacterial infection during the treatment of acute urinary tract infections | Indication |
| Dogs | Control of bacterial infection during the treatment of acute bacterial complications of distemper | Indication |
| Dogs | Control of bacterial infection during the treatment of acute respiratory tract infections | Indication |
| Dogs | Control of bacterial infection during the treatment of acute alimentary tract infections | Indication |
| Dogs | Control of bacterial infection during the treatment of wound infections | Indication |
| Dogs | Control of bacterial infection during the treatment of abscesses | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during treatment of acute strangles | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during respiratory infections | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during acute urogenital infections | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during wound infections | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during abscesses | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Tribrissen 120 Tablets, Tribrissen 30 Tablets, Tribrissen 480 Tablets, Tribrissen 960 Tablets | Intervet Inc. | 2 |
| Tribrissen 24% Injection | Intervet Inc. | 2 |
| Tribrissen 48% Injection | Intervet Inc. | 2 |
| Di-Trim Tablets | Zoetis Inc. | 2 |
| Tribrissen 400 Oral Paste | Intervet Inc. | 2 |
| Di-Trim 24% | Zoetis Inc. | 2 |
| Di-Trim 48% Injection | Zoetis Inc. | 2 |
| Di-Trim 400 Paste | Zoetis Inc. | 2 |
| Tribrissen 60 Oral Suspension | Intervet Inc. | 2 |
| ReBalance | Pegasus Laboratories Inc. | 2 |
| EQUISUL-SDT | Aurora Pharmaceutical Inc. | 2 |
| Uniprim Powder | Neogen Corp. | 2 |
| Tucoprim Powder | Zoetis Inc. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.6 | acidic |
| pKa2 | 2.03 | Basic |
| pKa3 | 1.41 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | GPCR | IC50 | 6.03 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | IC50 | 4.96 | WOMBAT-PK | |||||
| Aurora kinase A | Kinase | IC50 | 4.68 | CHEMBL | |||||
| High affinity choline transporter 1 | Transporter | IC50 | 4.24 | WOMBAT-PK | |||||
| Dihydropteroate synthase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| D00587 | KEGG_DRUG |
| 547-32-0 | SECONDARY_CAS_RN |
| 4017497 | VANDF |
| C0038675 | UMLSCUI |
| CHEBI:9328 | CHEBI |
| CHEMBL439 | ChEMBL_ID |
| CHEMBL1200351 | ChEMBL_ID |
| DB00359 | DRUGBANK_ID |
| D013411 | MESH_DESCRIPTOR_UI |
| 5215 | PUBCHEM_CID |
| 421 | INN_ID |
| 0N7609K889 | UNII |
| 10171 | RXNORM |
| 13920 | MMSL |
| 2022 | MMSL |
| 5523 | MMSL |
| 7798 | MMSL |
| 87818 | MMSL |
| d00118 | MMSL |
| 002814 | NDDF |
| 014626 | NDDF |
| 371400009 | SNOMEDCT_US |
| 74523009 | SNOMEDCT_US |
| 768490003 | SNOMEDCT_US |
| 422 | INN_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Sulfadiazine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0757 | TABLET | 500 mg | ORAL | ANDA | 18 sections |
| SULFADIAZINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-757 | TABLET | 500 mg | ORAL | ANDA | 19 sections |